Potent and selective xanthine-based inhibitors of phosphodiesterase 5
作者:Nichola J. Arnold、Ruth Arnold、David Beer、Gurdip Bhalay、Stephen P. Collingwood、Sarah Craig、Nicholas Devereux、Mark Dodds、Andrew R. Dunstan、Robin A. Fairhurst、David Farr、Joseph D. Fullerton、Angela Glen、Sylvie Gomez、Sandra Haberthuer、Julia D.I. Hatto、Colin Howes、Darryl Jones、Thomas H. Keller、Beate Leuenberger、Heinz E. Moser、Irene Muller、Reto Naef、Paul A. Nicklin、David A. Sandham、Katharine L. Turner、Morris F. Tweed、Simon J. Watson、Mauro Zurini
DOI:10.1016/j.bmcl.2006.11.019
日期:2007.4
Inhibitors of PDE5 are useful therapeutic agents for treatment of erectile dysfunction. A series of novel xanthine derivatives has been identified as potentinhibitors of PDE5, with good levels of selectivity against other PDE isoforms, including PDE6. Studies in the dog indicate excellent oral bioavailability for compound 21.
In clinical studies, several inhibitors of phosphodiesterase 5 (PDE5) have demonstrated utility in the treatment of erectile dysfunction. We describe herein a series of 8-aryl xanthine derivatives which function as potent PDE5 inhibitors with, in many cases, high levels of selectivity versus other PDE isoforms. (C) 2002 Elsevier Science Ltd. All rights reserved.
MERLOS, M.;GOMEZ, L.;VERICAT, M. L.;BARTROLI, J.;GARCIA-RAFANELL, J.;FORN+, EUR. J. MED. CHEM., 25,(1990) N, C. 653-658
作者:MERLOS, M.、GOMEZ, L.、VERICAT, M. L.、BARTROLI, J.、GARCIA-RAFANELL, J.、FORN+